Home » Healthcare » UAE Chronic Pain Market

UAE Chronic Pain Market By Indication (Neuropathic Pain, Arthritis Pain, Chronic Back Pain, Cancer Pain, Migraine); By Drug Class (Opioids, Non-Steroidal, Anticonvulsants, Antidepressants, Drug Class 5); By Application (Musculoskeletal, Neuropathy, Oncology, Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others); By Geography (Abu Dhabi, Dubai, Sharjah, Ajman, Fujairah, Ras Al Khaimah, Umm Al Quwain) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2019-2022
Base Year	2023
Forecast Period	2024-2032
UAE Chronic Pain Market Size 2024	USD 178.81 million
UAE Chronic Pain Market, CAGR	3.01%
UAE Chronic Pain Market Size 2032	USD 237.96 million

Market Overview

The UAE chronic pain market is projected to grow from USD 178.81 million in 2023 to USD 237.96 million by 2032, at a CAGR of 3.01%.

The UAE chronic pain market is driven by an increasing prevalence of chronic conditions such as arthritis, back pain, and neuropathy, alongside an aging population more susceptible to long-term ailments. Advancements in pain management treatments, including the growing adoption of non-invasive therapies and personalized care, contribute to market expansion. Moreover, greater awareness about chronic pain management among healthcare providers and patients is boosting demand for effective solutions. The rising availability of advanced analgesic medications and technologies further enhances treatment options, supporting market growth. Additionally, government initiatives to improve healthcare infrastructure and provide better access to pain management services are expected to fuel the market. The trend toward integrating digital health technologies, including telemedicine and mobile applications for pain management, is also gaining momentum, offering patients more convenient and accessible options for managing chronic pain. These factors collectively drive the market’s positive growth trajectory.

The UAE chronic pain management market is primarily concentrated in major cities like Abu Dhabi and Dubai, where advanced healthcare infrastructure, a high standard of living, and increasing awareness of chronic pain treatments drive demand. These regions feature specialized medical centers and a diverse population, including a growing elderly demographic, fueling the need for effective pain management solutions. In addition to public healthcare services, private healthcare providers are playing a crucial role in delivering pain relief treatments. Key players in the market include prominent pharmaceutical and medical device companies like Abbott Laboratories, Pfizer Inc., Eli Lilly & Company, and Merck & Co. Inc., which offer a wide range of pain management products, including opioids, NSAIDs, and non-pharmacological treatments. The adoption of innovative pain management devices, digital health solutions, and alternative therapies is also gaining traction, further expanding the market opportunities in the UAE.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Insights

The UAE chronic pain market was valued at USD 178.81 million in 2023 and is projected to reach USD 237.96 million by 2032, growing at a CAGR of 3.01%.
Rising prevalence of chronic diseases, especially among the aging population, is driving the demand for pain management solutions.
Sedentary lifestyles and increased stress levels also contribute to the growing cases of chronic pain.
Limited access to specialized pain management professionals and the underutilization of pain management services remain key challenges.
Stigma surrounding chronic pain, along with misconceptions and underreporting, hinders effective treatment.
Dubai and Abu Dhabi lead the market due to their robust healthcare infrastructure and rising awareness of pain management therapies.
Technological advancements in pain management, such as wearable devices and digital health solutions, are expanding treatment options.

Market Drivers

Favorable Regulatory Environment

The UAE’s supportive regulatory framework for medical devices and pharmaceuticals has facilitated the introduction of innovative pain management solutions. The government’s proactive approach in regulating and approving new medical technologies has contributed to the market’s growth. For instance, the UAE’s Vision 2031 and Vision 2071 plans emphasize the importance of healthcare innovation and the establishment of world-class medical facilities. Furthermore, the establishment of favorable reimbursement policies has made pain management treatments more accessible and affordable for patients. These policies ensure that patients can receive timely treatment without the burden of high costs, further driving the demand for effective chronic pain solutions in the UAE. The combination of a supportive regulatory environment and favorable reimbursement schemes strengthens the market’s potential for growth.

Growing Awareness and Demand for Effective Pain Management

Improved healthcare infrastructure in the UAE has played a pivotal role in increasing access to chronic pain management treatments. The presence of advanced medical facilities and skilled healthcare professionals has led to the widespread availability of various therapeutic options. For instance, the UAE government has made significant investments in healthcare infrastructure, enhancing accessibility and affordability for patients seeking pain management solutions. In addition, the UAE government’s significant investments in the healthcare sector have enhanced accessibility and affordability for patients seeking pain management solutions. Along with these developments, rising patient awareness about the importance of pain management has empowered individuals to seek timely treatment, thus improving their quality of life. Educational campaigns and initiatives aimed at raising awareness about chronic pain and its management have further driven the demand for effective pain relief solutions.

Rising Prevalence of Chronic Diseases

The aging population in the UAE is contributing significantly to the rise in chronic pain conditions. With a growing number of elderly individuals, the incidence of age-related diseases such as arthritis, osteoporosis, and neurological disorders has increased, often leading to chronic pain. Additionally, the sedentary lifestyle prevalent in modern UAE society, characterized by desk jobs and reduced physical activity, has become a significant factor in the rise of lifestyle diseases like obesity, diabetes, and cardiovascular conditions, all of which contribute to chronic pain. Furthermore, the fast-paced work culture and high-stress environment in the UAE have led to a surge in stress-related disorders, such as anxiety, depression, and fibromyalgia, which commonly manifest as chronic pain, adding to the overall burden of pain management.

Technological Advancements in Pain Management

Technological innovations have revolutionized the chronic pain management landscape in the UAE. The development of advanced pain management devices, including neurostimulators, transcutaneous electrical nerve stimulation (TENS) units, and wearable pain relief devices, has provided patients with more effective and non-invasive treatment options. Additionally, the integration of digital health solutions, such as telemedicine and remote patient monitoring, has significantly improved access to pain management services, offering convenience and enhanced care for patients. These technological advancements have not only broadened the range of available treatments but also made pain management more accessible to a larger segment of the population.

Market Trends

Increasing Prevalence of Chronic Conditions and Growing Awareness

The rising prevalence of chronic diseases in the UAE is driven by an aging population, a sedentary lifestyle, and increased stress levels. As the elderly population continues to grow, there is a higher incidence of age-related chronic conditions such as arthritis, osteoporosis, and neurological disorders, leading to a significant rise in chronic pain cases. Additionally, the modern, urban lifestyle in the UAE, with its sedentary jobs and reduced physical activity, contributes to lifestyle diseases like obesity, diabetes, and cardiovascular issues, which often result in chronic pain. The fast-paced work culture also exacerbates stress, anxiety, and depression, conditions that can manifest as chronic pain syndromes such as fibromyalgia and tension headaches. Alongside these health trends, there is a growing awareness among patients and healthcare providers about the importance of effective pain management. Government initiatives and awareness campaigns have empowered individuals to seek appropriate treatments, driving demand for effective pain relief solutions.

Technological Advancements and a Supportive Regulatory Environment

Technological advancements in pain management are significantly influencing the UAE market, providing patients with more effective and non-invasive treatment options. The development of innovative devices, such as neurostimulators, transcutaneous electrical nerve stimulation (TENS) units, and wearable pain relief devices, offers alternative approaches to managing chronic pain. For instance, the use of spinal cord stimulators has emerged as a promising approach to managing chronic pain in the UAE. Moreover, the adoption of digital health solutions, including telemedicine and remote patient monitoring, is improving access to pain management services, enhancing patient care, and making treatments more accessible. In tandem with these technological developments, the UAE’s supportive regulatory environment facilitates the introduction of new pain management therapies. The government’s favorable policies surrounding medical devices and pharmaceuticals ensure that innovative solutions can be rapidly introduced to the market. Additionally, the availability of reimbursement policies makes pain management treatments more affordable, further boosting their accessibility to patients. This combination of technological advancements and regulatory support fosters a positive environment for the continued growth of chronic pain management in the UAE.

Market Challenges Analysis

Lack of Specialized Pain Management Professionals and Limited Access to Care

One of the significant challenges facing the UAE’s chronic pain management market is the shortage of specialized pain management professionals. There is a considerable gap in the number of qualified pain specialists, which limits the availability of specialized care for patients suffering from chronic pain. For instance, a report highlighted that only a small percentage of chronic pain patients in the UAE have access to specialized pain clinics, with most being treated in general healthcare settings. This shortage is particularly evident in rural and remote areas, where access to healthcare services is already constrained. As a result, many patients struggle to find the specialized care they need, which can lead to delayed or inadequate treatment. Furthermore, underutilization of pain management services is prevalent due to a lack of awareness among patients about available treatment options or reluctance to seek specialized care. Patients may either not recognize the importance of pain management or face logistical and financial barriers, further exacerbating their condition. This gap in specialized care presents a significant challenge to addressing the growing demand for chronic pain treatments in the region.

Stigma, High Costs, and Regulatory Barriers

Stigma and misconceptions about chronic pain also pose major challenges to effective pain management in the UAE. Many patients with chronic pain experience stigmatization, as the condition is often misunderstood, both by the general public and healthcare providers. This lack of understanding can lead to delayed diagnoses and inadequate treatment plans. Additionally, patients may underreport their pain due to fear of being perceived as drug-seeking or concerns about potential side effects, which compounds the difficulty in managing chronic pain. Financial barriers further complicate access to proper care. Many advanced pain management therapies and medications are expensive, making them unaffordable for a large segment of the population. Furthermore, limited reimbursement coverage for chronic pain treatments adds to the financial burden on patients. On top of these challenges, the strict regulatory environment surrounding medical devices and pharmaceuticals can delay the introduction of innovative treatments, and complex reimbursement processes further hinder timely access to care. The combination of stigma, high treatment costs, and regulatory complexities presents significant obstacles in improving the quality of care and accessibility for those suffering from chronic pain in the UAE.

Market Opportunities

The UAE chronic pain management market presents significant opportunities driven by a growing demand for advanced pain relief solutions and expanding healthcare infrastructure. As the population ages and the prevalence of chronic conditions such as arthritis, diabetes, and cardiovascular diseases rises, there is an increasing need for specialized pain management treatments. The country’s robust healthcare system, supported by substantial government investments, provides a favorable environment for introducing new therapies and technologies. This growing demand creates opportunities for the development and commercialization of innovative pain management devices, such as neurostimulators and wearable pain relief units, that offer non-invasive treatment options. Additionally, the rising awareness among patients and healthcare providers about chronic pain management further fuels the market potential, opening avenues for educational campaigns and patient support services.

Another promising opportunity lies in the adoption of digital health technologies in the UAE’s healthcare sector. The increasing acceptance of telemedicine and remote monitoring solutions provides a platform for delivering pain management services to a broader patient base, especially in rural and underserved areas. These technologies not only improve access to treatment but also enhance patient compliance and outcomes by allowing for continuous monitoring and personalized care plans. Moreover, with the shift toward non-opioid treatments and multimodal pain management approaches, there is potential for the development of alternative therapies that address both physical and psychological aspects of chronic pain. As the UAE government continues to prioritize healthcare reforms and improve reimbursement policies, the chronic pain management market stands to benefit from a combination of technological innovations, growing demand for comprehensive care, and regulatory support.

Market Segmentation Analysis:

By Indication:

The UAE chronic pain market is primarily segmented by indication, with neuropathic pain, arthritis pain, chronic back pain, cancer pain, and migraine being the key contributors. Neuropathic pain, often caused by nerve damage or conditions such as diabetes or multiple sclerosis, is one of the leading causes of chronic pain in the region, resulting in significant demand for effective management solutions. Arthritis pain, particularly in the elderly population, is another major segment, as conditions like osteoarthritis and rheumatoid arthritis are highly prevalent and often lead to long-term pain. Chronic back pain, often caused by poor posture or injuries, is a common issue among the UAE’s working population, further driving market demand. Cancer pain, associated with advanced cancer stages, remains a critical concern, as the need for effective pain relief solutions intensifies. Lastly, migraines, which affect a substantial portion of the population, contribute to the market’s demand for specialized pain management treatments.

By Drug Class:

The UAE chronic pain market is also segmented by drug class, with opioids, non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, antidepressants, and other drug classes playing significant roles in treatment. Opioids are widely used for managing moderate to severe pain, particularly in cancer and neuropathic pain, although concerns about addiction have influenced their usage. NSAIDs, including ibuprofen and aspirin, are commonly used for conditions like arthritis and chronic back pain, offering an accessible and effective solution for inflammation-induced pain. Anticonvulsants, such as gabapentin, are increasingly used to treat neuropathic pain, providing an alternative to opioids. Antidepressants, such as amitriptyline and duloxetine, are also prescribed for chronic pain management, especially for conditions like neuropathic pain and fibromyalgia. Lastly, other drug classes, including topical analgesics and muscle relaxants, are utilized to treat specific pain types, contributing to a diversified treatment landscape. This segmentation highlights the variety of therapeutic approaches available to manage chronic pain in the UAE.

Segments:

Based on Indication:

Neuropathic Pain
Arthritis Pain
Chronic Back Pain
Cancer Pain
Migraine

Based on Drug Class:

Opioids
Non-Steroidal
Anticonvulsants
Antidepressants
Drug Class 5

Based on Application:

Musculoskeletal
Neuropathy
Oncology
Others

Based on Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Others

Based on the Geography:

Abu Dhabi
Dubai
Sharjah
Ajman
Fujairah
Ras Al Khaimah
Umm Al Quwain

Regional Analysis

Abu Dhabi

Abu Dhabi holds a substantial market share, estimated at around 40% of the total chronic pain management market in the UAE. The city’s strong healthcare system, marked by advanced medical facilities and specialized pain management centers, contributes to this dominance. Abu Dhabi’s population is aging rapidly, increasing the prevalence of chronic pain conditions such as arthritis, cancer pain, and neuropathic pain. Additionally, the rising awareness of pain management solutions among healthcare professionals and patients has accelerated the demand for advanced treatment options. The city also benefits from government initiatives to improve healthcare access, including substantial investments in medical research and the introduction of cutting-edge pain relief technologies. Furthermore, Abu Dhabi’s strategic focus on enhancing healthcare quality through partnerships with international medical institutions has further driven the growth of the chronic pain market.

Dubai

In contrast, Dubai holds a slightly smaller market share of approximately 35% but continues to be a key player in the region. The city’s advanced healthcare infrastructure, cosmopolitan lifestyle, and high level of medical tourism contribute significantly to the chronic pain market. Dubai’s healthcare system is known for its cutting-edge facilities and specialists, particularly in fields like oncology, neurology, and orthopedics, which are crucial for chronic pain management. The growing expatriate population in Dubai, along with a rising number of older adults, increases the demand for chronic pain treatments. Additionally, Dubai’s high disposable income and focus on wellness and healthcare innovations have made it a hub for the latest in pain management technologies, such as digital health solutions and wearable pain relief devices. The combination of these factors continues to fuel market growth and demand for chronic pain management solutions in Dubai.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Abbott Laboratories
Pfizer Inc.
Eli Lilly & Company
Cara Therapeutics
Chattem (Sanofi)
Endo International plc
Merck & Co. Inc.
Hoffmann-La Roche AG
Novaremed AG
Company 11
Company 12
Company 13
Company 14

Competitive Analysis

The UAE chronic pain management market is highly competitive, with several leading pharmaceutical and medical device companies vying for market share. Key players include Abbott Laboratories, Pfizer Inc., Eli Lilly & Company, Cara Therapeutics, Chattem (Sanofi), Endo International plc, Merck & Co. Inc., F. Hoffmann-La Roche AG, and Novaremed AG. Leading players in the market focus on providing both pharmacological and non-pharmacological treatments, including opioids, NSAIDs, anticonvulsants, antidepressants, and advanced pain management devices. Companies are increasingly emphasizing the development of innovative solutions such as neurostimulators, wearable pain relief devices, and digital health technologies to cater to the diverse needs of patients. The market is also witnessing a shift towards non-opioid pain management due to rising concerns about opioid addiction and misuse. This has led to greater investment in alternative therapies, including physical therapy, acupuncture, and digital solutions for pain management. Furthermore, companies are strengthening their presence in the UAE by expanding healthcare partnerships, improving patient education, and focusing on accessibility to advanced treatments. The competition is intensified by the continuous need for product innovation, with a strong focus on non-invasive, cost-effective, and more personalized treatment options to meet the needs of a growing patient base. As the market matures, the key to success lies in the ability to adapt to emerging trends, such as digital health and multimodal pain management approaches.

Recent Developments

In July 2024, Boston Scientific Corporation announced positive five-year results for the Intracept Intraosseous Nerve Ablation System, presented at the American Society of Pain & Neuroscience (ASPN) conference in Miami Beach, Florida. The data, pooled from three clinical trials, highlight the effectiveness of the Intracept system in treating vertebrogenic low back pain, a condition caused by damage to vertebral endplates.
In April 2024, Vertex Pharmaceuticals announced significant progress in its suzetrigine pain program, an oral selective NaV1.8 pain signal inhibitor that is poised to become the first new class of medicine for acute and neuropathic pain in over two decades. Following positive Phase 3 results in January 2024, the FDA granted New Drug Application (NDA) submission for suzetrigine in moderate-to-severe acute pain.
In February 2024, CinCor Pharma, Inc. was acquired by AstraZeneca. Cincor is a clinical stage biopharmaceutical company based out of USA that is focused on developing novel treatments for severe hypertension and chronic kidney disease.
In January 2024, Bayer AG disclosed its plan to strengthen its pharmaceutical and consumer health businesses. This move will bolster the company’s American market presence.
In January 2024, Sanofi announced its acquisition of Inhibrx, Inc., aiming to incorporate a potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency into its pipeline.
In December 2023, Forever Cheer, a pharmaceutical company holding more than 10 global patents, selected Hong Kong as the launchpad for its innovative pain management drugs, aiming to expand its global footprint and significantly impact the healthcare industry
In August 2023, MOBE and Override, digital health innovators, partnered to introduce a shared savings program for chronic pain management. This initiative focuses on providing personalized pain treatment through data analytics and behavioral health coaching, with the goal of reducing healthcare costs.

Market Concentration & Characteristics

The UAE chronic pain management market exhibits moderate to high market concentration, with several key players controlling a significant share of the market. These companies range from global pharmaceutical giants to regional players, offering a diverse range of pain management products and services. The market is characterized by the presence of both well-established pharmaceutical companies and emerging players focusing on innovative non-opioid treatments and pain relief devices. The increasing adoption of advanced technologies, such as wearable pain management devices and digital health solutions, is reshaping the competitive landscape. Additionally, the market is heavily influenced by the growing demand for non-invasive and personalized pain management options, driving companies to invest in research and development. The increasing prevalence of chronic pain conditions, particularly among the aging population, has contributed to this trend. The market is also shaped by healthcare regulations and the emphasis on patient safety, which requires companies to adhere to stringent standards for the approval and distribution of pain management solutions. Furthermore, strong government investments in healthcare infrastructure and growing awareness about chronic pain and its treatments are key factors contributing to market growth. This dynamic environment encourages collaboration between pharmaceutical companies, healthcare providers, and technology firms to offer comprehensive pain management solutions tailored to the needs of the UAE population.

Report Coverage

The research report offers an in-depth analysis based on Indication, Drug Class, Application, Distribution Channel and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The UAE chronic pain management market is expected to continue growing due to the increasing prevalence of chronic pain conditions, particularly among the aging population.
Non-opioid pain management options will become more popular as concerns about opioid addiction drive demand for safer alternatives.
The adoption of digital health technologies, such as telemedicine and remote monitoring, will enhance patient access to pain management services.
Technological advancements in pain management devices, including wearable pain relief solutions, will improve treatment outcomes for patients.
The rising focus on personalized pain management approaches will lead to the development of customized treatment plans for patients.
Increased awareness campaigns and patient education will empower more individuals to seek appropriate treatment for chronic pain.
Government investments in healthcare infrastructure will continue to improve access to advanced pain management therapies.
The integration of complementary and alternative therapies, such as acupuncture and yoga, will expand treatment options for chronic pain.
Healthcare providers will increasingly adopt multimodal pain management strategies to address the complex nature of chronic pain.
The market will see more collaborations between pharmaceutical companies, medical device manufacturers, and healthcare providers to offer comprehensive pain management solutions.

CHAPTER NO. 1 : INTRODUCTION 20

1.1. Report Description 20

Purpose of the Report 20

USP & Key Offerings 20

1.2. Key Benefits for Stakeholders 20

1.3. Target Audience 21

1.4. Report Scope 21

CHAPTER NO. 2 : EXECUTIVE SUMMARY 22

2.1. CHRONIC PAIN Market Snapshot 22

2.2. UAE CHRONIC PAIN Market, 2018 – 2032 (USD Million) 23

CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 24

3.1. UAE-UAEraine and Israel-Palestine War Impacts 24

CHAPTER NO. 4 : CHRONIC PAIN MARKET – INDUSTRY ANALYSIS 25

4.1. Introduction 25

4.2. Market Drivers 26

4.3. Increasing incidences of arthritis and other painful disease 26

4.3.1. Newer technique for pain management 27

4.4. Market Restraints 28

4.5. Treatment costs are high 28

4.6. Market Opportunities 29

4.7. Market Opportunity Analysis 29

4.8. Porter’s Five Forces Analysis 30

4.9. Value Chain Analysis 31

4.10. Buying Criteria 32

CHAPTER NO. 5 : IMPORT EXPORT ANALYSIS 33

5.1. Import Analysis by UAE 33

5.1.1. UAE CHRONIC PAIN Market Import Volume/Revenue, By UAE, 2018 – 2023 33

5.2. Export Analysis by UAE 34

5.2.1. UAE CHRONIC PAIN Market Export Volume/Revenue, By UAE, 2018 – 2023 34

CHAPTER NO. 6 : DEMAND SUPPLY ANALYSIS 35

6.1. Demand Analysis by UAE 35

6.1.1. UAE CHRONIC PAIN Market Demand Volume/Revenue, By UAE, 2018 – 2023 35

6.2. Supply Analysis by UAE 36

6.2.1. UAE CHRONIC PAIN Market Supply Volume/Revenue, By UAE, 2018 – 2023 36

CHAPTER NO. 7 : PRODUCTION ANALYSIS 37

7.1. Production Analysis by UAE 37

7.1.1. UAE CHRONIC PAIN Market Production Volume/Revenue, By UAE, 2018 – 2023 37

CHAPTER NO. 8 : PRICE ANALYSIS 38

8.1. Price Analysis by Indication 38

8.1.1. UAE CHRONIC PAIN Market Price, By Indication, 2018 – 2023 38

8.1.2. UAE Indication Market Price, By Indication, 2018 – 2023 38

CHAPTER NO. 9 : RAW MATERIALS ANALYSIS 39

9.1. Key Raw Materials and Suppliers 39

9.2. Key Raw Materials Price Trend 39

CHAPTER NO. 10 : MANUFACTURING COST ANALYSIS 40

10.1. Manufacturing Cost Analysis 40

10.2. Manufacturing Process 40

CHAPTER NO. 11 : ANALYSIS COMPETITIVE LANDSCAPE 41

11.1. Company Market Share Analysis – 2023 41

11.1.1. UAE CHRONIC PAIN Market: Company Market Share, by Volume, 2023 41

11.1.2. UAE CHRONIC PAIN Market: Company Market Share, by Revenue, 2023 42

11.1.3. UAE CHRONIC PAIN Market: Top 6 Company Market Share, by Revenue, 2023 42

11.1.4. UAE CHRONIC PAIN Market: Top 3 Company Market Share, by Revenue, 2023 43

11.2. UAE CHRONIC PAIN Market Company Volume Market Share, 2023 44

11.3. UAE CHRONIC PAIN Market Company Revenue Market Share, 2023 45

11.4. Company Assessment Metrics, 2023 45

11.4.1. Stars 46

11.4.2. Emerging Leaders 46

11.4.3. Pervasive Players 46

11.4.4. Participants 46

11.5. Start-ups /SMEs Assessment Metrics, 2023 46

11.5.1. Progressive Companies 46

11.5.2. Responsive Companies 46

11.5.3. Dynamic Companies 46

11.5.4. Starting Blocks 46

11.6. Strategic Developments 47

11.6.1. Acquisitions & Mergers 47

New Product Launch 47

UAE Expansion 47

11.7. Key Players Product Matrix 48

CHAPTER NO. 12 : PESTEL & ADJACENT MARKET ANALYSIS 49

12.1. PESTEL 49

12.1.1. Political Factors 49

12.1.2. Economic Factors 49

12.1.3. Social Factors 49

12.1.4. Technological Factors 49

12.1.5. Environmental Factors 49

12.1.6. Legal Factors 49

12.2. Adjacent Market Analysis 49

CHAPTER NO. 13 : CHRONIC PAIN MARKET – BY INDICATION SEGMENT ANALYSIS 50

13.1. CHRONIC PAIN Market Overview, by Indication Segment 50

13.1.1. CHRONIC PAIN Market Revenue Share, By Indication, 2023 & 2032 51

13.1.2. CHRONIC PAIN Market Attractiveness Analysis, By Indication 52

13.1.3. Incremental Revenue Growth Opportunity, by Indication, 2024 – 2032 52

13.1.4. CHRONIC PAIN Market Revenue, By Indication, 2018, 2023, 2027 & 2032 53

13.2. Neuropathic Pain 54

13.3. Arthritis pain 55

13.4. Chronic Back pain 56

13.5. Cancer Pain 57

13.6. Migraine 58

CHAPTER NO. 14 : CHRONIC PAIN MARKET – BY DRUG CLASS SEGMENT ANALYSIS 59

14.1. CHRONIC PAIN Market Overview, by Drug Class Segment 59

14.1.1. CHRONIC PAIN Market Revenue Share, By Drug Class , 2023 & 2032 60

14.1.2. CHRONIC PAIN Market Attractiveness Analysis, By Drug Class 61

14.1.3. Incremental Revenue Growth Opportunity, by Drug Class , 2024 – 2032 61

14.1.4. CHRONIC PAIN Market Revenue, By Drug Class , 2018, 2023, 2027 & 2032 62

14.2. Opiods 63

14.3. Non steroidal 64

14.4. Anticonvulsants 65

14.5. Antidepressants: 66

14.6. Drug Class 5 67

CHAPTER NO. 15 : CHRONIC PAIN MARKET – BY APPLICATION ANALYSIS 68

15.1. CHRONIC PAIN Market Overview, by Application 68

15.1.1. CHRONIC PAIN Market Revenue Share, By End-user, 2023 & 2032 69

15.1.2. CHRONIC PAIN Market Attractiveness Analysis, By End-user 70

15.1.3. Incremental Revenue Growth Opportunity, by End-user, 2024 – 2032 70

15.1.4. CHRONIC PAIN Market Revenue, By End-user, 2018, 2023, 2027 & 2032 71

15.2. Musculoskeletal 72

15.3. Neuropathy 73

15.4. Oncology 74

15.5. Others 75

CHAPTER NO. 16 : CHRONIC PAIN MARKET – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS 76

16.1. CHRONIC PAIN Market Overview, by Distribution Channel Segment 76

16.1.1. CHRONIC PAIN Market Revenue Share, By Distribution Channel, 2023 & 2032 77

16.1.2. CHRONIC PAIN Market Attractiveness Analysis, By Distribution Channel 78

16.1.3. Incremental Revenue Growth Opportunity, by Distribution Channel, 2024 – 2032 78

16.1.4. CHRONIC PAIN Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 79

16.2. Hospital Pharmacies 80

16.3. Retail Pharmacies 81

16.4. Others 82

CHAPTER NO. 17 : CHRONIC PAIN MARKET – UAE ANALYSIS 83

17.1. Indication 83

17.1.1. UAE CHRONIC PAIN Market Revenue, By Indication, 2018 – 2023 (USD Million) 83

17.2. UAE CHRONIC PAIN Market Revenue, By Indication, 2024 – 2032 (USD Million) 83

17.3. Drug Class 84

17.3.1. UAE CHRONIC PAIN Market Revenue, By Drug Class , 2018 – 2023 (USD Million) 84

17.3.2. UAE CHRONIC PAIN Market Revenue, By Drug Class , 2024 – 2032 (USD Million) 84

17.4. End-user 85

17.4.1. UAE CHRONIC PAIN Market Revenue, By End-user, 2018 – 2023 (USD Million) 85

17.4.2. UAE CHRONIC PAIN Market Revenue, By End-user, 2024 – 2032 (USD Million) 85

17.5. Technology 86

17.5.1. UAE CHRONIC PAIN Market Revenue, By Technology, 2018 – 2023 (USD Million) 86

17.5.2. UAE CHRONIC PAIN Market Revenue, By Technology, 2024 – 2032 (USD Million) 86

17.6. Distribution Channel 87

17.6.1. UAE CHRONIC PAIN Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 87

17.6.2. UAE CHRONIC PAIN Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 87

CHAPTER NO. 18 : COMPANY PROFILES 88

18.1. Abbott Laboratories 88

18.1.1. Company Overview 88

18.1.2. Product Portfolio 88

18.1.3. Swot Analysis 88

18.2. Business Strategy 89

18.3. Financial Overview 89

18.4. Pfizer Inc. 90

18.5. Eli Lilly & Company 90

18.6. Cara Therapeutics 90

18.7. Chattem (Sanofi) 90

18.8. Endo International plc 90

18.9. Merck & Co. Inc. 90

18.10. F. Hoffmann-La Roche AG. 90

18.11. Novaremed AG. 90

18.12. Company 11 90

18.13. Company 12 90

18.14. Company 13 90

18.15. Company 14 90

List of Figures

FIG NO. 1. UAE CHRONIC PAIN Market Revenue, 2018 – 2032 (USD Million) 22

FIG NO. 2. Porter’s Five Forces Analysis for UAE CHRONIC PAIN Market 29

FIG NO. 3. Value Chain Analysis for UAE CHRONIC PAIN Market 30

FIG NO. 4. UAE CHRONIC PAIN Market Import Volume/Revenue, By UAE, 2018 – 2023 32

FIG NO. 5. UAE CHRONIC PAIN Market Export Volume/Revenue, By UAE, 2018 – 2023 33

FIG NO. 6. UAE CHRONIC PAIN Market Demand Volume/Revenue, By UAE, 2018 – 2023 34

FIG NO. 7. UAE CHRONIC PAIN Market Supply Volume/Revenue, By UAE, 2018 – 2023 35

FIG NO. 8. UAE CHRONIC PAIN Market Production Volume/Revenue, By UAE, 2018 – 2023 36

FIG NO. 9. UAE CHRONIC PAIN Market Price, By Indication, 2018 – 2023 37

FIG NO. 10. Raw Materials Price Trend Analysis, 2018 – 2023 38

FIG NO. 11. Manufacturing Cost Analysis 39

FIG NO. 12. Manufacturing Process 39

FIG NO. 13. Company Share Analysis, 2023 40

FIG NO. 14. Company Share Analysis, 2023 41

FIG NO. 15. Company Share Analysis, 2023 41

FIG NO. 16. Company Share Analysis, 2023 42

FIG NO. 17. CHRONIC PAIN Market – Company Volume Market Share, 2023 43

FIG NO. 18. CHRONIC PAIN Market – Company Revenue Market Share, 2023 44

FIG NO. 19. CHRONIC PAIN Market Revenue Share, By Indication, 2023 & 2032 50

FIG NO. 20. Market Attractiveness Analysis, By Indication 51

FIG NO. 21. Incremental Revenue Growth Opportunity by Indication, 2024 – 2032 51

FIG NO. 22. CHRONIC PAIN Market Revenue, By Indication, 2018, 2023, 2027 & 2032 52

FIG NO. 23. UAE CHRONIC PAIN Market for Neuropathic Pain, Revenue (USD Million) 2018 – 2032 53

FIG NO. 24. UAE CHRONIC PAIN Market for Arthritis pain, Revenue (USD Million) 2018 – 2032 54

FIG NO. 25. UAE CHRONIC PAIN Market for Chronic Back pain , Revenue (USD Million) 2018 – 2032 55

FIG NO. 26. UAE CHRONIC PAIN Market for Cancer Pain, Revenue (USD Million) 2018 – 2032 56

FIG NO. 27. UAE CHRONIC PAIN Market for Migraine, Revenue (USD Million) 2018 – 2032 57

FIG NO. 28. CHRONIC PAIN Market Revenue Share, By Drug Class , 2023 & 2032 59

FIG NO. 29. Market Attractiveness Analysis, By Drug Class 60

FIG NO. 30. Incremental Revenue Growth Opportunity by Drug Class , 2024 – 2032 60

FIG NO. 31. CHRONIC PAIN Market Revenue, By Drug Class , 2018, 2023, 2027 & 2032 61

FIG NO. 32. UAE CHRONIC PAIN Market for Opiods, Revenue (USD Million) 2018 – 2032 62

FIG NO. 33. UAE CHRONIC PAIN Market for Non steroidal , Revenue (USD Million) 2018 – 2032 63

FIG NO. 34. UAE CHRONIC PAIN Market for Anticonvulsants, Revenue (USD Million) 2018 – 2032 64

FIG NO. 35. UAE CHRONIC PAIN Market for Antidepressants:, Revenue (USD Million) 2018 – 2032 65

FIG NO. 36. UAE CHRONIC PAIN Market for Drug Class 5, Revenue (USD Million) 2018 – 2032 66

FIG NO. 37. CHRONIC PAIN Market Revenue Share, By End-user, 2023 & 2032 68

FIG NO. 38. Market Attractiveness Analysis, By End-user 69

FIG NO. 39. Incremental Revenue Growth Opportunity by End-user, 2024 – 2032 69

FIG NO. 40. CHRONIC PAIN Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70

FIG NO. 41. UAE CHRONIC PAIN Market for Musculoskeletal, Revenue (USD Million) 2018 – 2032 71

FIG NO. 42. UAE CHRONIC PAIN Market for Neuropathy, Revenue (USD Million) 2018 – 2032 72

FIG NO. 43. UAE CHRONIC PAIN Market for Oncology, Revenue (USD Million) 2018 – 2032 73

FIG NO. 44. UAE CHRONIC PAIN Market for Others, Revenue (USD Million) 2018 – 2032 74

FIG NO. 45. CHRONIC PAIN Market Revenue Share, By Distribution Channel, 2023 & 2032 76

FIG NO. 46. Market Attractiveness Analysis, By Distribution Channel 77

FIG NO. 47. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 77

FIG NO. 48. CHRONIC PAIN Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 78

FIG NO. 49. UAE CHRONIC PAIN Market for Hospital Pharmacies, Revenue (USD Million) 2018 – 2032 79

FIG NO. 50. UAE CHRONIC PAIN Market for Retail Pharmacies, Revenue (USD Million) 2018 – 2032 80

FIG NO. 51. UAE CHRONIC PAIN Market for Others, Revenue (USD Million) 2018 – 2032 81

List of Tables

TABLE NO. 1. : UAE CHRONIC PAIN Market: Snapshot 18

TABLE NO. 2. : Drivers for the CHRONIC PAIN Market: Impact Analysis 22

TABLE NO. 3. : Restraints for the CHRONIC PAIN Market: Impact Analysis 24

TABLE NO. 4. : UAE CHRONIC PAIN Market Revenue, By Indication, 2018 – 2023 34

TABLE NO. 5. : Key Raw Materials & Suppliers 35

TABLE NO. 6. : UAE CHRONIC PAIN Market Revenue, By Indication, 2018 – 2023 (USD Million) 89

TABLE NO. 7. : UAE CHRONIC PAIN Market Revenue, By Indication, 2024 – 2032 (USD Million) 89

TABLE NO. 8. : UAE CHRONIC PAIN Market Revenue, By Drug Class , 2018 – 2023 (USD Million) 90

TABLE NO. 9. : UAE CHRONIC PAIN Market Revenue, By Drug Class , 2024 – 2032 (USD Million) 90

TABLE NO. 10. : UAE CHRONIC PAIN Market Revenue, By End-user, 2018 – 2023 (USD Million) 91

TABLE NO. 11. : UAE CHRONIC PAIN Market Revenue, By End-user, 2024 – 2032 (USD Million) 91

TABLE NO. 12. : UAE CHRONIC PAIN Market Revenue, By Technology, 2018 – 2023 (USD Million) 92

TABLE NO. 13. : UAE CHRONIC PAIN Market Revenue, By Technology, 2024 – 2032 (USD Million) 92

TABLE NO. 14. : UAE CHRONIC PAIN Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 93

TABLE NO. 15. : UAE CHRONIC PAIN Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 93

Frequently Asked Questions:

What is the current size of the UAE Chronic Pain Market?

The UAE chronic pain market was valued at USD 178.81 million in 2023 and is projected to grow to USD 237.96 million by 2032, reflecting a CAGR of 3.01%.

What factors are driving the growth of the UAE Chronic Pain Market?

Growth is driven by an aging population, rising prevalence of chronic conditions such as arthritis, back pain, and neuropathy, advancements in pain management treatments, and greater awareness among healthcare providers and patients. Government investments in healthcare infrastructure and the adoption of digital health technologies also contribute to market expansion.

What are the key segments within the UAE Chronic Pain Market?

The market is segmented by indication (neuropathic pain, arthritis pain, chronic back pain, cancer pain, and migraine), drug class (opioids, NSAIDs, anticonvulsants, antidepressants, and others), application (musculoskeletal, neuropathy, oncology), distribution channels (hospital pharmacies, retail pharmacies), and geography (Abu Dhabi, Dubai, Sharjah, and other regions).

What are some challenges faced by the UAE Chronic Pain Market?

Challenges include a shortage of specialized pain management professionals, limited access to care in rural and remote areas, stigma and misconceptions about chronic pain, high costs of advanced treatments, and regulatory barriers that delay the introduction of innovative therapies.

Who are the major players in the UAE Chronic Pain Market?

Key players include Abbott Laboratories, Pfizer Inc., Eli Lilly & Company, Cara Therapeutics, Merck & Co. Inc., Chattem (Sanofi), Endo International plc, F. Hoffmann-La Roche AG, and Novaremed AG, offering a mix of pharmacological and non-pharmacological pain management solutions.

Purchase Options

Single User

$2699

Multi User

$3699

Custom Report

$5699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –